中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

56 records (took 0.029 seconds)

    HEMODIALYSIS CATHETER SLEEVE
    12.
    发明申请
    HEMODIALYSIS CATHETER SLEEVE 审中-公开
    HEMODIALYSIS导管套管

    公开(公告)号：US20170072129A1

    公开(公告)日：2017-03-16

    申请号：US15257252

    申请日：2016-09-06

    Applicant: Surmodics, Inc.

    Inventor： Joram Slager ,  Joe McGonigle ,  Anh Tri La ,  David E. Babcock ,  Bruce Jelle ,  Aleksey Kurdyumov ,  Timothy M. Kloke ,  Charlie Olson ,  Gary Maharaj ,  Nathan Lockwood

    IPC: A61M1/36 ,  A61M39/02 ,  A61M25/10

    Abstract: A hemodialysis vascular access device includes a proximal end sized and shaped to sealably couple to a hemodialysis catheter, a movable structure coupled to the proximal end, a fixation structure coupled to the movable region and sized and shaped for fixation on a patient, an elongated sleeve coupled to the fixation structure and sized and shaped for insertion into a patient's vasculature, and a valve at a distal end of the internal lumen. When a hemodialysis catheter is inserted into the device and coupled to the proximal end, distal movement of the proximal end relative to the fixation structure biases a distal end of the hemodialysis catheter from a position inside the elongated sleeve through a valve out of the device and into the patient's blood.

    Abstract translation: 血液透析血管通路装置包括尺寸和形状可密封地连接到血液透析导管的近端，耦合到近端的可移动结构，联接到可移动区域的尺寸和形状用于固定在患者身上的细长套筒 耦合到所述固定结构，并且其尺寸和形状用于插入到患者的脉管系统中，以及在所述内腔的远端处的阀。 当血液透析导管插入装置并且联接到近端时，近端相对于固定结构的远端运动通过穿过装置的阀将细胞套筒内的位置偏离血液透析导管的远端， 进入病人的血液。

    Hydrophobic active agent particle coatings and methods for treatment
    13.
    发明授权
    Hydrophobic active agent particle coatings and methods for treatment 有权

    公开(公告)号：US11123459B2

    公开(公告)日：2021-09-21

    申请号：US15842110

    申请日：2017-12-14

    Applicant: Surmodics, Inc.

    Inventor： Joram Slager ,  Rick Murphy

    IPC: A61L29/16 ,  A61L29/08 ,  C08L39/06 ,  C08L67/04 ,  A61M25/10

    Abstract: Drug delivery coatings and devices including the same are described herein. The drug delivery coating has a first coated layer with non-ionic polymer and photogroups, a second coated layer with acid polymer in contact and hydrogen bonded with the first layer, particles with hydrophobic therapeutic agent, and cationic agent. The coating can be provided on a balloon catheter, and the particles and cationic agent can be transferred to tissue during a medical procedure, such as an angioplasty procedure, for a therapeutic effect.

    Macrolide particulates, methods for preparation, and medical devices associated therewith
    16.
    发明授权
    Macrolide particulates, methods for preparation, and medical devices associated therewith 有权

    公开(公告)号：US10449180B2

    公开(公告)日：2019-10-22

    申请号：US15959589

    申请日：2018-04-23

    Applicant: Surmodics, Inc.

    Inventor： Joram Slager

    IPC: A61K31/435 ,  A61K31/436 ,  A61K9/00 ,  A61K9/107 ,  A61K9/19 ,  A61K9/51 ,  A61L29/08 ,  A61L29/16 ,  A61K9/14 ,  A61K9/16

    Abstract: The disclosure provides macrolide particulates including a macrolide therapeutic agent such as rapamycin at high concentration in the particulate. In one method the particulates are made by adding a composition containing an polyoxyethylene sorbitan n-acyl ester, poly(ethyleneimine), or alkylated quaternary ammonium salt to a composition including macrolide dissolved in an alcohol such as ethanol. In another method the particulates are made by adding a non-solvent composition to a composition including macrolide and an alkyl-substituted chromanol dissolved in an alcohol such as ethanol. The formed macrolide particulates have one or more desirable properties including sizes in the range of 0.1 μm to 10 μm, spherical or near spherical shapes, low polydispersity, and/or stability. The macrolide particulates can be used for therapeutic compositions, or in association with an implantable or insertable medical device, such as associated with a polymeric coating on a device.

    Delivery of coated hydrophobic active agent particles
    17.
    发明授权
    Delivery of coated hydrophobic active agent particles 有权

    公开(公告)号：US10213529B2

    公开(公告)日：2019-02-26

    申请号：US13793390

    申请日：2013-03-11

    Applicant: SurModics, Inc.

    Inventor： Joram Slager

    IPC: A61L29/16 ,  A61L29/08 ,  A61L29/14 ,  A61K31/337 ,  A61K9/50

    Abstract: Embodiments of the invention include devices and coatings for devices including coated hydrophobic active agent particles. In an embodiment, the invention includes a drug delivery device including a substrate; and coated therapeutic agent particles disposed on the substrate, the coated therapeutic agent particles comprising a particulate hydrophobic therapeutic agent; and a cationic agent in contact with the particulate hydrophobic therapeutic agent. Other embodiments are also included herein.

    COMPOSITION AND METHOD FOR DELIVERY OF HYDROPHOBIC ACTIVE AGENTS
    19.
    发明申请
    COMPOSITION AND METHOD FOR DELIVERY OF HYDROPHOBIC ACTIVE AGENTS 有权
    用于输送疏水活性剂的组合物和方法

    公开(公告)号：US20170072057A1

    公开(公告)日：2017-03-16

    申请号：US15357496

    申请日：2016-11-21

    Applicant: Surmodics, Inc.

    Inventor： Joseph Ventura ,  Shannon Wadman ,  Joram Slager ,  Joseph Schmidt McGonigle ,  Robert W. Hergenrother

    IPC: A61K47/34 ,  A61K9/08 ,  A61K31/337

    CPC classification number: A61K47/34 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/337 ,  A61L27/18 ,  A61L27/54 ,  A61L2300/416 ,  A61L2300/63 ,  A61L2400/06 ,  C08L79/02

    Abstract: Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed. In one embodiment, the delivery composition includes a cationic delivery agent, a therapeutically effective amount of a hydrophobic active agent and a pharmaceutically acceptable aqueous carrier. In one embodiment, the cationic delivery agent includes polyethyleneimine (PEI). In a more specific embodiment, the cationic delivery agent includes branched PEI. Methods of making the delivery composition, as well as kits and methods of use are also disclosed.

    Abstract translation: 本文公开了用于施用疏水性活性剂的递送组合物。 在一个实施方案中，公开了用于向患者的组织或器官局部施用疏水性活性剂的递送组合物。 在一个实施方案中，递送组合物包括阳离子递送剂，治疗有效量的疏水活性剂和药学上可接受的水性载体。 在一个实施方案中，阳离子递送剂包括聚乙烯亚胺（PEI）。 在更具体的实施方案中，阳离子递送剂包括支链PEI。 还公开了制备递送组合物的方法，以及试剂盒和使用方法。

    SOLVENT METHODS FOR PREPARING CRYSTALLINE MACROLIDE PARTICULATES, COMPOSITIONS, AND ARTICLES CONTAINING PARTICULATES
    20.
    发明申请
    SOLVENT METHODS FOR PREPARING CRYSTALLINE MACROLIDE PARTICULATES, COMPOSITIONS, AND ARTICLES CONTAINING PARTICULATES 有权
    用于制备晶体结构的颗粒，组合物和含有颗粒物的制品的溶剂方法

    公开(公告)号：US20150017219A1

    公开(公告)日：2015-01-15

    申请号：US14303309

    申请日：2014-06-12

    Applicant: SURMODICS, INC.

    Inventor： Joram Slager ,  Aleksey V. Kurdyumov ,  Toni M. Heyer

    IPC: A61L29/16 ,  C07D498/18

    CPC classification number: A61L29/16 ,  A61K9/0019 ,  A61K9/14 ,  A61K31/436 ,  A61L2300/416 ,  C07D498/18 ,  Y10T428/2982

    Abstract: The invention provides therapeutic particulates including a macrolide, such as rapamycin, in solid state crystalline form, having a size of 20 μm or less, or 10 μm or less. The particulates are formed in one method by preparing a composition with a macrolide and first (e.g., xylene) and second (e.g., an alcohol, acetone, or acetonitrile) solvents. In the composition a maximum solubility for the macrolide that is greater than a maximum solubility of the macrolide dissolved in either the first or second solvent individually. The first and second solvents are then evaporated from the composition to provide the macrolide particulates. In another method, the particulates can be formed by a method including sonication and stirring/evaporation steps, and the particulates can be obtained from a supersaturated solution, formed during the process. Particulates display desirable low polydispersity, and can be used in therapeutic compositions, or can be associated with an implantable or insertable medical device for the treatment of a subject.

    Abstract translation: 本发明提供治疗性微粒，其包括固体状结晶形式的大环内酯如雷帕霉素，其尺寸为20μm或更小或10μm或更小。 通过制备具有大环内酯和第一（例如二甲苯）和第二（例如醇，丙酮或乙腈）溶剂的组合物来形成颗粒。 在组合物中，大环内酯的最大溶解度大于单独溶解在第一或第二溶剂中的大环内酯的最大溶解度。 然后将第一和第二溶剂从组合物中蒸发以提供大环内酯颗粒。 在另一种方法中，颗粒可以通过包括超声处理和搅拌/蒸发步骤的方法形成，并且颗粒可以从在过程中形成的过饱和溶液获得。 颗粒显示出期望的低多分散性，并且可以用于治疗组合物，或者可以与用于治疗受试者的可植入或可插入的医疗装置相关联。

Patent Agency Ranking